Guan-Nan Zhang

TL;DR: Clinical rationale for combination of conventional chemotherapy and targeted anticancer agents is provided and strategy to reposition one FDA-approved anticancer drug regorafenib to overcome the resistance of another FDA- approved, widely used chemotherapeutic paclitaxel may be a promising direction for the field of adjuvant chemotherapy.

TL;DR: Overall, this study indicated that bafetinib reversed ABCB1- and ABCG2-mediated MDR by blocking the drug efflux function of these transporters.

TL;DR: The in vitro findings indicated that β-elemene potentiates the cytotoxic effects of various antineoplastic drugs in cell lines overexpressing the ABCB1 transporter and that this is due to the inhibition of the efflux component of the ABC B1 transporter.

TL;DR: It is suggested that the combination of topotecan and PD153035 could be a promising therapeutic strategy to attenuate the resistance to topOTecan, as well as other anticancer drugs, mediated by the overexpression of ABCG2.

TL;DR: It is concluded that ORA reverseABCB1-mediated MDR by competitively inhibiting the ABCB1 drug efflux function by reverse the resistance to paclitaxel and vincristine in ABCB 1-overexpressing SW620/Ad300 and HEK/ABCB 1 cells.